Company intelligence / Profile preview

PromiSight

Ownership: Private
Development stage: Other

Overview

PROMinsight has developed and commercialized a digital CAT-based PROMs platform that significantly reduces data collection time by up to 70% compared to traditional methods. Their validated tools are integrated into clinical workflows globally and have been well received by clinicians and patients for improving quality-of-life measurement in ophthalmology and related fields. The company continues to expand its suite of condition-specific item banks/platform modules.

Therapeutic areas: OphthalmologyEndocrinology
Modalities: Non-pharmacological therapyDevice
Industry: Digital Health Medical Devices

Partnerships

Not explicitly listed; works with CROs, pharmaceutical companies, hospitals/universities globally as clients/users.

Beyond the preview

Go deeper on PromiSight.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PromiSight.

Explore the full profile